司库奇尤单抗治疗中重度斑块型银屑病的效果观察

Efficacy of Secukinumab in Treatment of Moderate and Severe Plaque Psoriasis

目的:探讨司库奇尤单抗治疗中重度斑块型银屑病的效果。方法:选取2020年1月—2022年12月张家界市人民医院收治的40例中重度斑块型银屑病患者作为研究对象,根据随机数字表法分为观察组和对照组,各20例。对照组给予外用药物治疗,观察组在对照组基础上采用司库奇尤单抗进行治疗。比较两组严重性指数(PASI)评分、炎性因子水平、临床疗效、生活质量评分、不良反应发生情况。结果:治疗后,观察组PASI评分低于对照组,差异有统计学意义(P=0.000)。治疗后,观察组肿瘤坏死因子、白细胞介素-17水平低于对照组,差异有统计学意义(P=0.000)。观察组治疗总有效率高于对照组,差异有统计学意义(P=0.033)。治疗后,观察组生理、心理、环境、社会领域评分高于对照组,差异有统计学意义(P=0.000)。两组不良反应发生率比较,差异无统计学意义(P=1.000)。结论:司库奇尤单抗治疗中重度斑块型银屑病可迅速降低炎性反应,提高治疗效果,安全性较高。

Objective:To explore the effect of secukinumab in the treatment of moderate and severe plaque psoriasis.Methods:A total of 40 patients with moderate and severe plaque psoriasis treated in Zhangjiajie People's Hospital from January 2020 to December 2022 were selected as the study subjects.They were divided into control group and observation group according to random number table method,with 20 cases in each group.The control group was treated with topical drugs,and the observation group was treated with secukinumab on the basis of control group.The Psoriasis Area and Severity Index(PASI)score,inflammatory factor levels,clinical efficacy,quality of life score,and occurrence of adverse reactions in two groups were compared.Results:After treatment,the PASI score in the observation group was lower than that in the control group,and the difference was statistically significant(P=0.000).After treatment,the levels of tumor necrosis factor and interleukin-17 in the observation group were lower than those in the control group,and the difference was statistically significant(P=0.000).The total effective rate of treatment in the observation group was higher than that in the control group,and the difference was statistically significant(P=0.033).After treatment,the scores of physical,psychological,environmental and social domains in the observation group were higher than those in the control group,and the differences were statistically significant(P=0.000).There was no significant difference in the incidence of adverse reactions between the two groups(P=1.000).Conclusion:Secukinumab in the treatment of moderate and severe plaque psoriasis can rapidly reduce inflammatory response and improve the treatment effect with higher safety.